timothy sykes logo

Stock News

ImmunityBio Stock On the Rise: Is It A Long-Term Investment or Short-Term Gain?

Timothy SykesAvatar
Written by Timothy Sykes
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

ImmunityBio Inc. sees an impressive stock rise, trading up by 31.35 percent on Friday, likely driven by investor enthusiasm over promising clinical trial results and potential FDA approval of its innovative cancer immunotherapy treatment.

Recent Highlights and Market Moves

  • Phase 1 clinical trials for a new CAR-NK cell therapy in Africa targeting relapsed B-cell non-Hodgkin lymphoma have begun. Data is expected by 2025.

Candlestick Chart

Live Update at 08:51:43 EST: On Friday, October 25, 2024 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 31.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • The company recently joined the Jefferies London Healthcare Conference, showcasing innovation in immunotherapy and FDA-approved treatments.

  • ImmunityBio has commenced a clinical trial for CAR-NK cell therapy, either solo or combined with the standard treatment rituximab for certain lymphoma cases.

Quick Overview of ImmunityBio’s Financial Health

ImmunityBio, famed for its bold strides in cancer immunotherapy, has recently stirred the waters with its new ventures and conference participation. Despite facing challenges, their financials offer a glimpse into a landscape both demanding and promising. The company’s revenue, though modest at $622k, displays ambitious growth metrics over the past few years, a hike echoed in their strategic advancements and pipeline projects.

Now, digging beneath the surface reveals some hitches; by numbers like a negative EBIT margin of -30,189.6 and EBITDA margin of -27,726.5, pointing to considerable hurdles at play. This financial stress hints at operational troubles, yet the reactions from market spectators and the clinical trials underway could buoy investor confidence. The QUILT 106 trial on CAR-NK cell therapy bolsters that belief, highlighting ImmunityBio’s commitment to scientific progression.

Their liquidity might evoke mixed feelings with a current ratio standing at 3.9, suggestive of stability, yet caution is urged since the profitability indicators linger far from ideal. With no positive free cash flows and the hefty load of debt resting heavily, the enterprise remains encumbered, hanging between vast debt obligations and ambitious scientific pursuits.

Breaking Down the Recent Surge

Clinical Trials Opening New Horizons

The recent buzz around ImmunityBio has a lot to do with its Phase 1 trial for CAR-NK cell therapy against relapsed non-Hodgkin lymphoma. As the first such study in Africa, it’s a milestone not only for the company but potentially the continent’s medical landscape. The anticipation surrounding the trial reflects on the company’s stock, as this breakthrough could redefine treatment protocols if the data turns favorable by 2025.

Strategies Showcased at the Healthcare Conference

Participating in the Jefferies London Healthcare Conference amplified the company’s visibility amongst stakeholders and experts. The presence underscored ImmunityBio’s drive towards exploring new immunotherapy frontiers, aiming for synergies that could sustain long-term investor interest. This visibility, while not immediately transforming into revenue, lays groundwork for future deals and collaborations.

More Breaking News

Unveiling Potentials with New Patient Trials

Beginning trials with a CAR-NK cell therapy targeting lymphoma marks another strategic foot forward. Addressing relapsed lymphoma cases with experimental therapy either alone or with rituximab reflects fearless ambition—an ambition that resonates with investors attuned to scientific novelties. This development, while still in early stages, implies a formidable commitment to diversifying therapeutic avenues.

Conclusions and Outlooks

The latest endeavors cast ImmunityBio as both a dynamic player in the biotech realm and a narrative of potential, not without challenges. Current stock movements bring focus on speculative hopes tethered to research outcomes and strategic showcases more than robust financial outcomes. Long haul investors or those inclined towards game-changing biotech paths might find the developments intriguing though not unencumbered by risks.

In landscapes where medical feats meet financial parameters, ImmunityBio’s story unfolds complex yet enticing layers. While strides in lymphoma therapies spark excitement, there is an ever-present need for sustainable operational efficiencies. The next years could determine whether ImmunityBio leaps to pioneering success, shaping both medical landscapes and investors’ portfolios.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.


How much has this post helped you?


Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”